Cited by 432HIV-related health complications and treatmentsHIV/AIDS Research and InterventionsHIV/AIDS drug development and treatment

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Relative risk of cardiovascular disease among people living with HIV : a systematic review and meta‐analysis

Open access

Islam, FM, Wu, J, Jansson, J, Wilson, DP·2012·HIV Medicine

DOI 10.1111/j.1468-1293.2012.00996.x

Open this paper in CoChat — free account Open PDF

Abstract

Objectives: The aim of this study was to estimate the relative risk of cardiovascular disease ( CVD ) among people living with HIV ( PLHIV ) compared with the HIV ‐uninfected population. Methods: We conducted a systematic review and meta‐analysis of studies from the peer‐reviewed literature. We searched the M edline database for relevant journal articles published before A ugust 2010. Eligible studies were observational and randomized controlled trials, reporting CVD , defined as myocardial infarction ( MI ), ischaemic heart disease, cardiovascular and cerebrovascular events or coronary heart disease among HIV ‐positive adults. Pooled relative risks were calculated for various groupings, including different classes of antiretroviral therapy ( ART ). Results: The relative risk of CVD was 1.61 [95% confidence interval ( CI ) 1.43–1.81] among PLHIV without ART compared with HIV ‐uninfected people. The relative risk of CVD was 2.00 (95% CI 1.70–2.37) among PLHIV on ART compared with HIV ‐uninfected people and 1.52 (95% CI 1.35–1.70) compared with treatment‐naïve PLHIV . We estimate the relative risk of CVD associated with protease inhibitor ( PI )‐, nucleoside reverse transcriptase inhibitor‐ and nonnucleoside reverse transcriptase inhibitor‐based ART to be 1.11 (95% CI 1.05–1.17), 1.05 (95% CI 1.01–1.10) and 1.04 (95% CI 0.99–1.09) per year of exposure, respectively. Not all ART was associated with increased risk; specifically, lopinavir/ritonavir and abacavir were associated with the greater risk and the relative risk of MI for PI ‐based versus non‐ PI ‐based ART was 1.41 (95% CI 1.20–1.65). Conclusion: PLHIV are at increased risk of cardiovascular disease. Although effective in prolonging survival, ART (in particular PI ‐based regimens) is related to further increased risk of CVD events among people at highest initial absolute risk of cardiovascular disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1468-1293.2012.00996.x

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,393

Show all 40 references

Research works printed but not linked: 6

UNAIDS, 2010, Global report: UNAIDS report on the global AIDS epidemic 2010
BedimoR WestfallA DrechslerH TebasP editors.Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era.5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town South Africa 2009[Abstract MOAB202].
BenitoR PinillaJ LabargaPet al. editors.Comparison of cardiovascular risk factors between HIV‐infected patients and non‐infected general population.The 14th International AIDS Conference. Barcelona Spain July2002[Abstract B10290].
DurandM SheehyO BarilJ‐G LelorierJ TremblayC editors.Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec's public health insurance database (QPHID).5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town South Africa 2009[Abstract TUPEB175].
HolmbergSD MoormanAC TongTCet al. editors.Protease inhibitor drug use and adverse cardiovascular events in ambulatory HIV‐infected patients.The 14th International AIDS Conference. Barcelona Spain July2002[Abstract TuPeB4494].
KleinD HurleyL SilverbergM HorbergM QuesenberryC SidneyS editors.Surveillance Data for Myocardial Infarction Hospitalizations among HIV+ and HIV‐ Northern Californians: 1994–2006.14th Conference on Retroviruses and Opportunistic Infections. Los Angeles CA February 2007 [Abstract 807].

Sorted by citations

Items 301–400 of 432

Thrombotic and cardiovascular events in HIV infection (Review)
Dryllis, G., Vasilopoulou, M., Politou, M., Gerogkiokas, A., Pittaras, T., Zoumpourlis, V., Spandidos, D. A., & Gialeraki, A. E. (2025) · Biomedical Reports · doi:10.3892/br.2025.2000 · Cited by 3
“Among HIV‑infected patients, those on ART had a 1.52‑fold higher CVD risk than treatment‑naïve individuals (43).”
Influential
HDL dysfunction: a role in the pathogenesis of cardiometabolic syndrome in chronic HIV infection?
Markakis, K., Abadi, L. F., Kombe, A. J. K., Christodoulides, M., & Kelesidis, T. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156432 · Cited by 3
Ischemic Heart Disease in Chronic Hepatitis B: A Danish Nationwide Cohort Study
Lau, F. F., Bollerup, S., Engsig, F. N., Krarup, H. B., Mygind, L. H., Hansen, J. B., Madsen, L. G., Thielsen, P., Balslev, U., Nielsen, L. N., et al. (2022) · Clinical Epidemiology · doi:10.2147/clep.s361910 · Cited by 3
“Predictably, we found male sex, comorbidity, T2DM, and not being employed to significantly increase the rate of development of IHD.”
BackgroundInfluential
An Integrated mHealth App for Smoking Cessation in Black Smokers With HIV: Protocol for a Randomized Controlled Trial
Bizier, A., Jones, A., Businelle, M. S., Kezbers, K. M., Hoeppner, B. B., Giordano, T. P., Thai, J. M., Charles, J. J., Montgomery, A., Gallagher, M. W., et al. (2024) · JMIR Research Protocols · doi:10.2196/52090 · Cited by 3
“Indeed, cigarette smoking is a leading risk factor for HIV-related and non–HIV-related morbidity and mortality among people with HIV/AIDS [11,12], even among those taking antiretroviral medications [13], and contributes to more life-years lost than HIV-related complications among those effectively…”
Background
Preferences for Hypertension Care in Malawi: A Discrete Choice Experiment Among People Living with Hypertension, With and Without HIV
Hoffman, R. M., Phiri, K., Kalande, P., Whitehead, H. S., Moses, A., Rockers, P. C., Tseng, C., Talama, G. C., Banda, J. C., van Oosterhout, J. J., et al. (2024) · AIDS and Behavior · doi:10.1007/s10461-024-04492-y · Cited by 3
QTc interval prolongation and its associated factors among HIV infected patients on ART in Mettu Town
Befkadu, Z., & Girma, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-79808-y · Cited by 3
“This risk is further increased in HIV-infected patients who are on antiretroviral therapy (ART) 8–11 .”
Modelling health outcomes of a decade of HIV, malaria and tuberculosis initiatives, Malawi
Mangal, T. D., Molaro, M., Nkhoma, D., Colbourn, T., Collins, J. H., Janoušková, E., Graham, M. M., Lin, I. L., Mnjowe, E., Mwenyenkulu, T. E., et al. (2025) · Bulletin of the World Health Organization · doi:10.2471/blt.24.292439 · Cited by 5
Myocardial Infarction Type 4b in Human Immunodeficiency Virus-Infected Patient
Cybula, A., Szymański, F. M., Platek, A. E., & Karpiński, G. (2014) · Korean Circulation Journal · doi:10.4070/kcj.2014.44.1.42 · Cited by 3
Use of HMG-CoA Reductase Inhibitors in the HIV Population: Implications for Individualized Treatment Selection
Advani, A., Patel, M. J., Pichardo, R. V., Whitty, Y., & Advani, S. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.3.262 · Cited by 3
“The relative risk of developing CVD in HIV patients has been estimated to be 61% higher than in non-HIV patients.(6) The manifestation of coronary atherosclerosis in HIV patients is hypothesized to be due to a higher prevalence of conventional risk factors (smoking, dyslipidemia, hypertension, and insulin abnormalitie…”
Background
"I don't want to look sick skinny": Perceptions of Body Image and Weight Loss in Hispanics Living with HIV in South Texas.
Abel, J. W., Allen, O., Bullock, D., Finley, E., Walter, E. A., Schnarrs, P. W., & Taylor, B. S. (2018) · PubMed · Cited by 3
The pharmacological management of cardiovascular disease in people living with HIV (PLWH)
Corbacho, N., Mur, I., Molas, M. E., Vidal, F., & Domingo, P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1856075 · Cited by 4
“whelming evidence that PLWH are at increased risk of cardiovascular events [2].”
Background
Prevalence of selected cardiometabolic risk factors in the global ART-naïve HIV infected population: A protocol for a systematic review and meta-analysis
Ebasone, P. V., Peer, N., Dzudié, A., & Kengne, A. P. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286789 · Cited by 4
A 10-Years Risk of Cardiovascular Disease Among HIV-Positive Individuals Using BMI-Based Framingham Risk Score in Indonesia
Lindayani, L., Purnama, H., Nurhayati, N., Sudrajat, D. A., & Taryudi, T. (2021) · SAGE Open Nursing · doi:10.1177/2377960821989135 · Cited by 3
Masa ventricular izquierda en pacientes con infección VIH
Olalla, J., Pombo, M., del Arco, A., Lima, J. D. L. T., Urdiales, D., & García‐Alegría, J. (2013) · Revista Clínica Española · doi:10.1016/j.rce.2013.02.001 · Cited by 3
The Assessment and Management of Coronary Artery Disease in Patients with HIV
Holloway, C. J. (2014) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000283 · Cited by 3
“A recent meta-analysis examining the risk of cardiovascular disease in patients with HIV without treatment found the relative risk of CVD was 61% higher compared to HIV uninfected patients [12].”
Effect of AIDS on Women Who Have Sex-Determined Health Issues
Sathekge, M. M., Maes, A., de Wiele, C. V., & Dadachova, E. (2014) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.06.001 · Cited by 3
HIV-Infektion
Bogner, J. R. (2012) · Der Internist · doi:10.1007/s00108-011-2972-7 · Cited by 3
Short-term folinic acid supplementation and aerobic exercise improve vascular reactivity in HIV-infected individuals
Grigoletti, S. S., Ribeiro, J. P., Sprinz, E., & Ribeiro, P. A. B. (2018) · HIV Clinical Trials · doi:10.1080/15284336.2018.1433769 · Cited by 3
Distinct profile of antiviral drugs effects in aortic and pulmonary endothelial cells revealed by high-content microscopy and cell painting assays
Grosicki, M., Wojnar‐Lason, K., Mosiołek, S., Mateuszuk, Ł., Stojak, M., & Chłopicki, S. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.117030 · Cited by 2
Depressive symptom clusters and biomarkers of monocyte activation, inflammation, and coagulation in people with HIV and depression
Crawford, C. A., Polanka, B. M., Wu, W., MacDonald, K. L., Gupta, S. K., & Stewart, J. C. (2024) · Journal of Health Psychology · doi:10.1177/13591053241270630 · Cited by 2
“CVD risk for PWH is increased compared to the general population (relative risk = 2.00, 95% CI 1.70–2.37), even when HIV is well-managed by antiretroviral therapy (ART; Islam et al., 2012).”
Influential
Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors
Ferrer, P. E., López, L., Pérez, J., Cabello, N., Núñez, M. J., Sagastagoitia-Fornie, I., Cotarelo, M., de Isla, L. P., & Estrada, V. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09850-8 · Cited by 3
“Putting the focus in cardiovascular disease (CVD), PLWH do present it more often than does the general population with the same characteristics [10, 11].”
Background
Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions
Smatti, M. K., Jan, Z., & Yassine, H. M. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100136 · Cited by 2
Diagnosis and Management of HIV-Associated Pulmonary Diseases in a Ryan White-Funded Primary Care Setting
Harrington, K. R. V., Staitieh, B. S., Nguyen, M. L., Colasanti, J. A., Sumitani, J., Marconi, V. C., & Auld, S. C. (2021) · AIDS Patient Care and STDs · doi:10.1089/apc.2021.0020 · Cited by 2
A Matter of Fat: Body Fat Distribution and Cardiometabolic Disease in Africa
Mahyoodeen, N. G., & Crowther, N. J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1558-4_3 · Cited by 3
Cardiac Abnormalities of People Living with HIV: A Comparative Study Between HAART Experience and Treatment Naïve Groups in Ghana
Owusu, I. K., Wiafe, Y. A., Opoku, S., Anto, E. O., & Acheamfour-Akowuah, E. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s366688 · Cited by 2
“Human immunodeficiency virus (HIV) infection is a global epidemic currently affecting about 38 million people worldwide.1 About 25 million people living with HIV (PLWHIV) are on highly active antiretroviral therapy (HAART), whilst over 12 million people are not receiving HAART.1 Despite the immense reduction in morbid…”
BackgroundInfluential
Reporting and recording of adverse drug reactions of highly active antiretroviral therapy by HIV infected patients and healthcare professionals respectively in the Ethekwini Metropolitan, of Kwa-Zulu Natal, South Africa: a cross sectional and retrospective comparative study
Zondi, S., & Naidoo, P. (2022) · Pan African Medical Journal · doi:10.11604/pamj.2022.42.218.32239 · Cited by 2
“These findings are similar to a metaanalyses study which showed that HIV patients on HAART have a 61% greater relative risk of developing cardiovascular disease than people who have not contracted HIV, furthermore HIV patients on HAART have 2 times greater relative risk of developing cardiovascular disease than HAART…”
Result
Association of HIV, cardiovascular risk factors, and carotid intimal media thickness: A cross-sectional study in Western Kenya
Farrant, M. T., Masyuko, S. J., Kinuthia, J., Osoti, A. O., Mogaka, J. N., Temu, T. M., Zifodya, J. S., Nakanjako, D., Ameda, F., Farquhar, C., et al. (2022) · Medicine · doi:10.1097/md.0000000000031366 · Cited by 2
“Human immunodeficiency virus (HIV) infection is associated with a nearly two-fold increased risk of cardiovascular disease (CVD).[1,2] Contributing factors include increased chronic inflammation and immune activation associated with HIV infection,[3,4] traditional CVD risk factors, and antiretroviral therapy (ART), pa…”
Background
The risk of new heart failure associated with protease inhibitor: Systematic scoping review
Gozun, M. K., Nishimura, Y., Techasatian, W., Pham, A. Q., Benavente, K., & Kewcharoen, J. (2023) · International Journal of STD & AIDS · doi:10.1177/09564624231196599 · Cited by 2
Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases
Biscetti, F., Polito, G., Rando, M. M., Nicolazzi, M. A., Eraso, L. H., DiMuzio, P. J., Massetti, M., Gasbarrini, A., & Flex, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020535 · Cited by 2
Clinical Application of Cardiac Magnetic Resonance in ART-Treated AIDS Males with Short Disease Duration
Hou, K., Fu, H., Xiong, W., Gao, Y., Xie, L., He, J., Feng, X., Zeng, T., Cai, L., Xiong, L., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12102417 · Cited by 2
Left ventricular mass in HIV-infected patients
Olalla, J., Pombo, M., del Arco, A., de la Torre, J., Urdiales, D., & García‐Alegría, J. (2013) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2013.02.001 · Cited by 2
Are Physical Fitness and CRP Related to Framingham Risk Score in HIV+ Adults?
Lewis, J. E., Poles, J., Garretson, E., Tiozzo, E., Goldberg, S., Campbell, C. S. G., Simões, H. G., Woolger, J. M., & Konefal, J. (2020) · American Journal of Lifestyle Medicine · doi:10.1177/1559827620904345 · Cited by 2
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study
Saumoy, M., Sánchez‐Quesada, J. L., Assoumou, L., Gatell, J. M., Gonzalez‐Cordón, A., Guaraldi, G., Domingo, P., Giacomelli, A., Connault, J., Katlama, C., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac117 · Cited by 2
Study Protocol for a Pilot Randomized Trial of a Virtual Occupational Therapy Fall Prevention Intervention for People With HIV and Alcohol Use
Shin, D., Gill, S. V., Kim, T. W., Magane, K. M., Mason, T., Heeren, T., Winter, M. R., Helfrich, C. A., & Saitz, R. (2022) · Substance Abuse Research and Treatment · doi:10.1177/11782218221145548 · Cited by 2
Epicardial fat density, coronary artery disease and inflammation in people living with HIV
Sadouni, M., Duquet-Armand, M., Alkeddeh, M. G., Far, M. E., Larouche-Anctil, E., Tremblay, C. L., Baril, J.-G., Trottier, B., Chartrand‐Lefebvre, C., Durand, M., et al. (2023) · Medicine · doi:10.1097/md.0000000000032980 · Cited by 2
“index (BMI),[5] smoking exposure,[14] high density lipoprotein-cholesterol,[4] low density lipoprotein-cholesterol,[9] antiretroviral therapy (ART) exposure duration,[7] non-nucleoside reverse transcriptase inhibitors exposure duration.”
Background
Cardiovascular imaging in South Africa: Is the heartache easing?
Scholtz, L. (2016) · South African Journal of Radiology · doi:10.4102/sajr.v20i2.1045 · Cited by 2
HIV and cardiovascular disease: comment on Islam et al.
Neaton, J. (2013) · HIV Medicine · doi:10.1111/hiv.12043 · Cited by 2
“I am writing concerning the paper by Islam et al. [1] titled ‘Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis’, which was published in the September 2012 issue of HIV Medicine. I believe that there are several errors in the paper that require correction. Figu…”
Influential
No evidence of a synergistic effect of HIV infection and diabetes mellitus type 2 on fat distribution, plasma adiponectin or inflammatory markers
Hove‐Skovsgaard, M., Abildgaard, J., Gelpi, M., Gaardbo, J. C., Kolte, L., Ullum, H., Trøseid, M., Lindegaard, B., & Nielsen, S. D. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05594-3 · Cited by 1
“However, a gap in life expectancy remains [2], and new challenges related to non-AIDS comorbidity have emerged including excess risk of cardiovascular disease (CVD) [3, 4].”
BackgroundInfluential
Comparison of Four Predictive Scores for Cardiovascular Risk in Mexican People with HIV
Oliva-Sánchez, P. F., Landeros-López, S., Rosas-Dossetti, M. M., Grobeisen-Levin, S., Islas-Martínez, J. A., Aznar-Guerra, D., Valdez-Celiz, A. P., & Soto-Ramírez, L. E. (2024) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2023.0085 · Cited by 1
Aproximación práctica del paciente con hipercolesterolemia en España. Documento de posicionamiento de SEMERGEN
Cinza‐Sanjurjo, S., Pallarés‐Carratalá, V., Rodríguez, Á. D., Fierro-González, D., Turégano-Yedro, M., & García, J. P. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102460 · Cited by 2
The hidden link between HIV and cardiomyopathy: unraveling HIV's impact on the heart
Awoyemi, T., Tolu-Akinnawo, O. Z., Greek, A., Adenuga, O., Asogwa, C. S., Ekundayo, I. O., Odusola, O. D., Fasehun, O. O., Ajayi, M. A., Ugoala, O. S., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1601430 · Cited by 1
“Protease inhibitor – based regimens, particularly those containing lopinavir/ritonavir and abacavir, have been associated with increased cardiovascular risk (e.g., MI relative risk ∼ 1.41 vs. non-PI regimens) (46).”
Influential
Antioxidant Agents and Their Potential Applications in Treating Various Chronic Diseases
Lakshmi, H. S., Subhashini, S., Rajkumar, D., & Ramesh, R. (2026) · Springer eBooks · doi:10.1007/978-981-95-3758-7_2 · Cited by 2
HIV and the brain: from AIDS to old age
Haddow, L. J., Cartledge, J. D., & Manji, H. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-6-s24 · Cited by 1
The Role of Infections and Microbes in Atherosclerosis
Fong, I. W. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1670-2_9 · Cited by 1
Acute coronary syndrome in human immunodeficiency virus patients: exploiting physiopathology to inform the clinical practice
Cerrato, E., Calcagno, A., D’Ascenzo, F., Biondi‐Zoccai, G., Quadri, G., Omedè, P., Abbate, A., Bonora, S., Moretti, C., & Gaïta, F. (2013) · OA Evidence-Based Medicine · doi:10.13172/2053-2636-1-1-542 · Cited by 1
Case 30-2012
Deeks, S. G., Gandhi, R. T., Chae, C. U., & Lewandrowski, K. B. (2012) · New England Journal of Medicine · doi:10.1056/nejmcpc1200090 · Cited by 1
A Review of Arterial Stiffness and HIV Infection in Adult Africans
Awotedu, K. O., & Iputo, J. E. (2016) · Journal of Hypertension Open Access · doi:10.4172/2167-1095.1000221 · Cited by 1
“The majority of the articles in Africa examined aspects of pericardial disease in HIV infected African subjects [71].”
BackgroundInfluential
Update on Pediatric Human Immunodeficiency Virus Infection
Smith, C., & McFarland, E. J. (2016) · Advances in Pediatrics · doi:10.1016/j.yapd.2016.04.007 · Cited by 1
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients
Pradat, P., Durant, J., Brochier, C., Trabaud, M., Cottalorda, J., Izopet, J., Raffi, F., Lucht, F., Gagnieu, M., Gatey, C., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw273 · Cited by 1
Novel Insights in the Management of Dyslipidemia in Patients With HIV Infection
Papagianni, M., Metallidis, S., & Τζιόμαλος, Κ. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0125-6 · Cited by 1
Changes in clinical indicators among human immunodeficiency virus patients who failed in antiretroviral therapy during 2004–2016 in Yunnan, China: an observational cohort study
Wang, P., Xu, J., Guo, B., Wang, J. K., Gao, L., Wang, Q., Jing, J., & Cheng, F. (2020) · Global Health Journal · doi:10.1016/j.glohj.2020.04.001 · Cited by 1
HIV and Dyslipidemia
Malvestutto, C., & Aberg, J. A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_23 · Cited by 1
Association of Inflammatory Biomarkers and Cardiovascular Risk Scores in an Italian Cohort of HIV Positive Patient Undergoing Antiretroviral Therapy
Falasca, K., Ucciferri, C., Auricchio, A., Reale, M., Costantini, E., & Vecchiet, J. (2022) · Current HIV Research · doi:10.2174/1570162x2002220623163705 · Cited by 1
Effect of 2018 American College of Cardiology/American Heart Association Guideline Change on Statin Prescription for People Living with HIV
Pan, M., Agovi, A. M., Anikpo, I. O., Fasanmi, E. O., Thompson, E. L., Reeves, J. M., Thompson, C. T., Johnson, M. E., Golub, V., & Ojha, R. P. (2022) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2023.102175 · Cited by 1
Heart transplantation and human immunodeficiency virus–navigating drug-drug interactions: a case report
Almangour, T. A., Skersick, P., Corbett, A., Rodgers, J. E., Chang, P. P., & Farel, C. E. (2023) · AIDS Research and Therapy · doi:10.1186/s12981-023-00551-x · Cited by 1
“Morbidity and mortality among people with HIV reflect comorbidities common in aging populations, with accelerated rates of vascular disease, including cardiovascular disease (CVD) often attributed to some ART and to HIV itself [2, 3].”
Background
Low levels of hypertension screening in HIV care clinics in rural Uganda: A mixed methods study
Atukunda, M., Charlebois, E. D., Twinamatsiko, B., Byamukama, A., Mutabazi, A., Akatukwasa, C., Ayebare, M., Tindimwebwa, W., Asiimwe, A., Lavoy, G., et al. (2024) · Open Research Europe · doi:10.12688/openreseurope.18094.1 · Cited by 1
HIV, hepatitis viruses and viral STIs: intertwined fates?
Cunningham, T. (2014) · Microbiology Australia · doi:10.1071/ma14025 · Cited by 1
Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome
Goodman, M. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-04414-9_44 · Cited by 2
“Many antiretroviral medications cause lipid disorders: along with tobacco use, viral cardiomyopathies, and inflammatory effects, cardiac disease has become a major threat to long-term health in this population [23].”
Background
HIV Associated Non-AIDS Conditions in Patients Aging with HIV
Guaraldi, G., Gomes, A. F., & Silva, A. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-20131-3_3 · Cited by 1
Prevalence of aortic valve dystrophy and insufficiency in a cohort of 255 HIV-positive patients followed-up in a cardiology department between 2012 and 2014
Jacomet, C., Illes, H.-G., Kwiatkowski, F., Vidal, M., Mrozek, N., Auméran, C., Corbin, V., Lesens, O., Laurichesse, H., & Bailly, P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.237 · Cited by 1
Epilepsy management in pregnant HIV+ women in sub-Saharan Africa, clinical aspects to consider: a scoping review
Menon, S., Beňová, L., & Mabeya, H. (2020) · BMC Medicine · doi:10.1186/s12916-020-01799-0 · Cited by 1
“Use of HAART has entailed an excess risk of seemingly unrelated non-AIDS conditions, such as hyperlipidemia [5], Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) [6], chronic kidney disease (CKD) [7], and cardiovascular diseases [8, 9].”
Background
Clinical relevance of adverse intracerebral artery remodeling in patients with HIV
Montecucco, F., & Carbone, F. (2015) · Neurology · doi:10.1212/wnl.0000000000001983 · Cited by 1
“Long-lived patients with HIV exhibited a marked acceleration of atherosclerosis with an increased risk of acute ischemic events.(3,4) Thus, long-term cardiovascular comorbidities might weaken the relative immune defense benefits induced by cART.”
Background
Infection and Cardiovascular Disease: The Atherosclerosis Risk in Communities Study
Cowan, L. (2017) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Efeitos do treinamento físico combinado periodizado e estatina em pessoas vivendo com HIV com dislipidemia: ensaio clínico randomizado, duplo-cego e placebo-controlado
Zanetti, H. R. (2018) · doi:10.14393/ufu.te.2019.1228 · Cited by 1
An evaluation of the role of platelet activation in HIV-related cardiovascular diseases onset
Dominick, L. (2021) · SUNScholar (Stellenbosch University) · Cited by 1
Chronic Nucleoside Reverse Transcriptase Inhibitors Disrupt Mitochondrial Homeostasis and Promote Premature Endothelial Senescence
Chen, Y. (2019) · Louisiana State University · doi:10.31390/gradschool_dissertations.4974 · Cited by 1
The Triglyceride-Glucose Index is a Predictor for Cardiovascular Diseases in People Living with HIV: Evidence from a Retrospectively Cohort Study in China, 2005-2022Preprint
Luo, Y., Sun, L., He, Y., Zhao, F., Shan, D., Bu, F., Ge, L., Li, X., Hu, Y., Lu, H., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4865056 · Cited by 1
A Decade of Progress in HIV, Malaria, and Tuberculosis Initiatives in MalawiPreprint
Mangal, T. D., Molaro, M., Nkhoma, D., Colbourn, T., Collins, J. H., Janoušková, E., Graham, M. M., Lin, I. L., Mnjowe, E., Mwenyenkulu, T. E., et al. (2024) · medRxiv · doi:10.1101/2024.10.08.24315077 · Cited by 1
Mechanisms of non-AIDS complications of HIV disease: role of hepatitis C co-infection
Bedimo, R. (2015)
Clinical Outcomes of Patients with HIV Undergoing Lead Extraction for Infectious and Noninfectious Indications
Cohen, J. A., Govea, A., & Carrillo, R. G. (2015) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.12773
HIV/AIDS and bone: an unrecognised threat?
Lange, W. D., Pretorius, J. J., Oosthuizen, D., & Marx, G. (2014) · South African Family Practice · doi:10.1080/20786190.2014.975485 · Cited by 1
[Hypertriglyceridemia-increased waist: may we improve the prediction of cardiovascular risk in human immunodeficiency virus infection?].
Vallecillo-Sánchez, G. (2012) · Medicina clínica (Ed. impresa) · doi:10.1016/j.medcli.2012.06.020
Inflammation and innate immune activation in chronic HIV infection
Jaworowski, A., & Hearps, A. C. (2014) · Microbiology Australia · doi:10.1071/ma14032
Srce i krvni Sudovi
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
For peer review only CD4+ cell count ≥200 cells/mm3 and Moderate Alcohol Consumption: Evidence of Protection against Coronary and other Arterial Disease Events in an 11$year Cohort of HIV$ infected Patients on Antiretroviral Therapy
d'Azur, C., Reboud, V., Raffi, P., Mahy, F., Roux, S., Cuzin, P., Spire, L., & Leport, C. (2012)
Was bei älteren HIV-Patienten zu beachten ist
Wolf, E., & Hammond, A. J. (2015) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-015-3163-6
HIV and aging : age-associated chronic comorbidities among HIV-positive individuals on highly active antiretroviral therapy in British Columbia, Canada
Gali, B. (2016) · cIRcle (University of British Columbia) · doi:10.14288/1.0224440
Hypertriglyceridemia-increased waist: may we improve the prediction of cardiovascular risk in human immunodeficiency virus infection?
Interna, S. D. M. (2016)
Human Immunodeficiency Virus infection, asymptomatic atherosclerosis, and inflammation: A candidate gene study
Lladó, L. I. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
AVALIAÇÃO DO RISCO CARDIOVASCULAR ATRAVÉS DOS INDICADORES DE OBESIDADE E DE DISTRIBUIÇÃO DA GORDURA COR PORAL EM PORTADORES DE HIV VIRGENS DE TRATAMENTO ANTIR R ETROVIRAL
Chagas, E., & Clínica, M. E. P. (2013)
Trauma and Immunosuppressive Diseases
van Aswegen, H., & Morrow, B. M. (2015) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781783266524_0003
Systolic function evaluated with cardiovascular magnetic resonance imaging in HIV-infected patients
Scholtz, L., Plessis, A. D., Andronikou, S., Swart, A., Stoltz, A. C., Khan, A., & Moosa, A. (2016) · South African Journal of Radiology · doi:10.4102/sajr.v20i2.1044
A Culturally Targeted Smoking Cessation/HIV Medication Adherence Intervention for African American MSM
Jones, K. (2016) · Figshare
Cytomegalovirus IgG in HIV+ persons on anti-retroviral therapy: characterisation and association with insulin resistance
Brunt, S. J. (2016) · UWA Profiles and Research Repository (University of Western Australia)
HIV/AIDS HASTALARINDA KALP VE DAMAR HASTALIKLARI
Karabay, O., & Karabay, M. (2017) · Online Türk Sağlık Bilimleri Dergisi · doi:10.26453/otjhs.333883
Cardiovascular Risk Prediction in Patients With HIV Infection
Τζιόμαλος, Κ. (2019) · Future Virology · doi:10.2217/fvl-2019-0131
Insomnia and Mechanistic Pathways to Atherosclerotic CVD in HIV
Polanka, B. M. (2020) · Purdue e-Pubs (Purdue University System) · doi:10.25394/pgs.12685520
Morphological and Histopathological Study of Autopsied Patients with Atherosclerosis and HIV
Oliveira, M. S., Torquato, B. G. S., Tsuji, S. Y., Aguiar, L. S., Juliano, G. R., da Silveira, L. A. M., Corrêa, R. R. M., Rocha, L. B., & Ferraz, M. L. D. F. (2020) · Current HIV Research · doi:10.2174/1570162x18999201029123356
Genügen ein Kreatininwert und ein Urinstix?
Seybold, U. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-0642-1
“Auch weitere kardiovaskuläre Risikofaktoren wie arterielle Hypertonie und Diabetes mellitus [13] treten bei Menschen mit HIVInfektion häuger auf, sodass das Risiko für kardiovaskuläre Erkrankungen bei ihnen generell erhöht ist [14], was wiederum mit einer erhöhten renalen Morbidität einhergeht [15].”
Background
Genügen ein Kreatininwert und ein Urinstix?: Nierenerkrankungen bei HIV-Patienten
Seybold, U. (2020) · MMW - Fortschritte der Medizin
Cardiovascular risk and liver transplantation in HIV patients. Are HIV infected liver transplant recipients at higher risk?
Vinaixa, C., Herreras, J., Blanes, M., Maupoey, J., Berenguer, M., Prieto, M., & Aguilera, V. (2021) · Journal of Liver Transplantation · doi:10.1016/j.liver.2021.100005
A Spatial Analysis of Hypertension Prevalence in Rural and Urban MalawiPreprint
Burns, J. J., Crampin, A. C., Price, A., Grundy, C., & Carpenter, J. R. (2021) · medRxiv · doi:10.1101/2021.04.23.21255979
The effect of eligibility for antiretroviral therapy on body mass index and blood pressure in KwaZulu-Natal, South Africa
Kuber, A., Reuter, A., Geldsetzer, P., Chimbindi, N., Moshabela, M., Tanser, F. C., Bärnighausen, T., & Vollmer, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-94057-z
What triggered my heart attack
Morton, J. (2019) · HIV Nursing
A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis
Cusato, J., Calcagno, A., Antonucci, M., Marinaro, L., Avataneo, V., Nicolò, A. D., Bonora, S., Perri, G. D., & D’Avolio, A. (2022) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.20.02739-1
HIV/AIDS
Naar, S., MacDonell, K. K., & Cockern, S. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816000-8.00012-8
Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome
Goodman, M. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-54441-6_44 · Cited by 1
Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome
Goodman, M. D. (2020) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_44-2
Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome
Goodman, M. D. (2015) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_44-1
High Prevalence of Lower Extremity Medial Arterial Calcification in HIV-infected Patients With and Without Chronic Renal Disease: A Vascular Ultrasound Cross-sectional Study
Višković, K., Marinelli, A., Nedeljko, K., Bržan, P. P., Bogdanić, N., & Begovać, J. (2022) · The Open AIDS Journal · doi:10.2174/18746136-v16-e221226-2022-11

Authors: Islam, F., Wu, J., Jansson, J., & Wilson, D.
Affiliations: The Kirby Institute Faculty of Medicine University of New South Wales Sydney NSW Australia
UNSW Sydney (AU)
Corresponding author: Wilson, DP
ORCID: Wu, J
Jansson, J
Venue: HIV Medicine
Publisher: Wiley
Published: 2012-03-14
Volume: 13
Issue: 8
Pages: 453-468
ISSN: 1464-2662 (ISSN-L)
1468-1293
DOI: 10.1111/j.1468-1293.2012.00996.x
OpenAlex: W1677033108
Cited by: 432
References: 40
Citations by year: 2026: 13 · 2025: 16 · 2024: 28 · 2023: 19 · 2022: 31 · 2021: 39 · 2020: 42 · 2019: 28 · 2018: 44 · 2017: 34 · 2016: 40 · 2015: 29 · 2014: 27 · 2013: 26 · 2012: 15
FWCI: 6.87
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: HIV Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Australian Government
Medical Research Council
Australian Research Council (DP1093026, FT0991990)
National Health and Medical Research Council (630495)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords: cardiovascular disease, people living with HIV, antiretroviral therapy, protease inhibitors, myocardial infarction, ischemic heart disease, coronary artery disease, cerebrovascular events, lopinavir/ritonavir, abacavir, cardiovascular risk
MeSH terms: Adult, Cardiovascular Diseases, Humans, Protease Inhibitors, Risk Factors, HIV Infections, Incidence, Reverse Transcriptase Inhibitors, Anti-Retroviral Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Relative risk of cardiovascular disease among people living with HIV : a systematic review and meta‐analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks